Literature DB >> 1847886

Nonenzymatic glycosylation of HDL and impaired HDL-receptor-mediated cholesterol efflux.

P B Duell1, J F Oram, E L Bierman.   

Abstract

Previous studies have shown that nonenzymatic glycosylation of high-density lipoprotein (HDL) inhibits high-affinity binding to cultured cells and the candidate HDL-receptor protein. Because binding of HDL to its receptor is required for HDL-receptor-mediated cholesterol efflux from cells, we hypothesized that glycosylated HDL3 would have reduced ability to remove cholesterol from cells. HDL3 was glycosylated in vitro to achieve up to 40-50% reductions in free-lysine residues. Glycosylated HDL3 had a slightly greater ability than control HDL3 to sequester cholesterol directly from the plasma membrane, as predicted by changes in lipid composition. This process is independent of HDL-receptor binding and should not be influenced by reduced binding of HDL3. In contrast, efflux of intracellular cholesterol from cells, which is HDL-receptor dependent, was reduced 25-40%. The ability of glycosylated HDL3 to diminish cholesterol esterification was significantly reduced, indicating reduced net cholesterol efflux. Steady-state efflux of LDL-derived cholesterol was also markedly reduced. These findings suggest that nonenzymatically glycosylated HDL is functionally abnormal and might contribute to the accelerated development of atherosclerosis in patients with diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1847886     DOI: 10.2337/diab.40.3.377

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  30 in total

1.  Effect of the nonenzymatic glycosylation of high density lipoprotein-3 on the cholesterol ester transfer protein activity.

Authors:  B Lemkadem; D Loiseau; G Larcher; Y Malthiery; F Foussard
Journal:  Lipids       Date:  1999-12       Impact factor: 1.880

2.  [The role of AGEs and ROS in atherosclerosis].

Authors:  Alin Stirban
Journal:  Herz       Date:  2010-05       Impact factor: 1.443

3.  High glucose levels do not directly impair cellular binding of HDL3 or HDL-mediated efflux of cholesterol from human skin fibroblasts.

Authors:  P B Duell; E L Bierman
Journal:  Acta Diabetol       Date:  1991       Impact factor: 4.280

Review 4.  Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms.

Authors:  Alin Stirban; Thomas Gawlowski; Michael Roden
Journal:  Mol Metab       Date:  2013-12-07       Impact factor: 7.422

5.  Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia.

Authors:  E Nobécourt; S Jacqueminet; B Hansel; S Chantepie; A Grimaldi; M J Chapman; A Kontush
Journal:  Diabetologia       Date:  2005-02-24       Impact factor: 10.122

6.  The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase.

Authors:  E Nobecourt; M J Davies; B E Brown; L K Curtiss; D J Bonnet; F Charlton; A S Januszewski; A J Jenkins; P J Barter; K-A Rye
Journal:  Diabetologia       Date:  2007-01-10       Impact factor: 10.122

Review 7.  HDL dysfunction in diabetes: causes and possible treatments.

Authors:  Dan Farbstein; Andrew P Levy
Journal:  Expert Rev Cardiovasc Ther       Date:  2012-03

8.  Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties.

Authors:  A Hoang; A J Murphy; M T Coughlan; M C Thomas; J M Forbes; R O'Brien; M E Cooper; J P F Chin-Dusting; D Sviridov
Journal:  Diabetologia       Date:  2007-06-20       Impact factor: 10.122

9.  Poor glycemic control is an independent risk factor for low HDL cholesterol in patients with type 2 diabetes.

Authors:  Alessandra Gatti; Marianna Maranghi; Simonetta Bacci; Claudio Carallo; Agostino Gnasso; Elisabetta Mandosi; Mara Fallarino; Susanna Morano; Vincenzo Trischitta; Sebastiano Filetti
Journal:  Diabetes Care       Date:  2009-06-01       Impact factor: 19.112

10.  Semiquantitative analysis of apolipoprotein A-I modified by advanced glycation end products in diabetes mellitus.

Authors:  Yoshifumi Kurosaki; Tomoaki Tsukushi; Shinichi Munekata; Tohru Akahoshi; Tatsumi Moriya; Zensuke Ogawa
Journal:  J Clin Lab Anal       Date:  2013-02-25       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.